Cargando…

A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy

Recently, tumor immunotherapy based on immune checkpoint inhibitors (ICI) has been introduced and widely adopted for various tumor types. Nevertheless, tumor immunotherapy has a few drawbacks, including significant uncertainty of outcome, the possibility of severe immune-related adverse events for p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Bingxiang, Lu, Mingjie, Yan, Linlin, Ge, Minghui, Ren, Yong, Wang, Ru, Shu, Yongqian, Hou, Lin, Guo, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695566/ https://www.ncbi.nlm.nih.gov/pubmed/34956232 http://dx.doi.org/10.3389/fimmu.2021.796647

Ejemplares similares

The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer
por: Sun, Xiaojiao, et al.
Publicado: (2022)

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures
por: Zhang, Xinke, et al.
Publicado: (2021)

Developing an m5C regulator–mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer
por: Zhang, Rixin, et al.
Publicado: (2023)

NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy
por: Xia, Jiaqi, et al.
Publicado: (2021)

Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis
por: Tu, Zewei, et al.
Publicado: (2022)

A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts
por: Ren, Qianhe, et al.
Publicado: (2023)

Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets
por: Guo, Aiyuan, et al.
Publicado: (2022)

Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis
por: Zhao, Guang, et al.
Publicado: (2022)

Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy
por: Chen, Yu, et al.
Publicado: (2022)

Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response
por: Li, Zhanzhan, et al.
Publicado: (2023)

A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer
por: Ren, Qianhe, et al.
Publicado: (2023)

The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response
por: Wu, Gujie, et al.
Publicado: (2022)

Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer
por: Cui, Hanxiao, et al.
Publicado: (2023)

Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma
por: Zhang, Xin, et al.
Publicado: (2023)

Comprehensive Analysis of a Cancer-Immunity Cycle–Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer
por: Hou, Yufang, et al.
Publicado: (2022)

Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis
por: Luo, Li-Zhi, et al.
Publicado: (2023)

PTPRO-related CD8(+) T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer
por: Dong, Hongmei, et al.
Publicado: (2022)

A signature for pan-cancer prognosis based on neutrophil extracellular traps
por: Zhang, Yi, et al.
Publicado: (2022)

Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer
por: Zhang, Qi, et al.
Publicado: (2022)

CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis
por: Li, Yang, et al.
Publicado: (2022)

Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer
por: Ju, Mingyi, et al.
Publicado: (2022)

Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis
por: Pan, Hongda, et al.
Publicado: (2022)

Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma
por: Zeng, Yu, et al.
Publicado: (2022)

CD8(+) T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma
por: Zhang, Minghui, et al.
Publicado: (2022)

Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy
por: Wang, Zheng, et al.
Publicado: (2022)

Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer
por: Song, Junquan, et al.
Publicado: (2022)

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
por: Dai, Weijing, et al.
Publicado: (2022)

A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer
por: Ding, Ke, et al.
Publicado: (2022)

Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis
por: Shu, Jianfeng, et al.
Publicado: (2023)

A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy
por: Li, He, et al.
Publicado: (2022)

Predictive biomarkers of colon cancer immunotherapy: Present and future
por: Hou, Wanting, et al.
Publicado: (2022)

Pan-Cancer Analysis Reveals the Signature of TMC Family of Genes as a Promising Biomarker for Prognosis and Immunotherapeutic Response
por: Song, Jing, et al.
Publicado: (2021)

Integrated bioinformatic analysis identified a novel prognostic pan-programmed cell death signature for bladder cancer
por: Zhang, Lusi, et al.
Publicado: (2022)

IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma
por: Liu, Chengdong, et al.
Publicado: (2022)

The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer
por: Zhao, Zidan, et al.
Publicado: (2023)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
por: Gao, Zijie, et al.
Publicado: (2022)

An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer
por: Wang, Ke-wei, et al.
Publicado: (2022)

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
por: Liu, Zhichao, et al.
Publicado: (2022)

Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer
por: Xu, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_763hpj3g166gd3tohocil4rvv2